Roger J M Brüggemann (Roger Brüggemann, Roger J Brüggemann, R J M Bruggemann, R J Brüggemann, R J M Brüggemann)

ResearcherID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 58

Top Topics

Extracorporeal Membrane Oxygenation

Candida Albicans

Top Venues

The Journal of antimicrobial chemotherapy

Clinical pharmacokinetics

Clinical microbiology reviews

This page only lists publications with an associated author ORCID identifier.

Publications

Koen P van Rhee, Catherijne A J Knibbe, P D van der Linden, Roger J M Brüggemann
Patients with Obesity Should be Recognised as a Special Patient Population During Drug Development of Antibacterial and Antifungal Agents; A Call to Action. Clinical pharmacokinetics 63 (1) (2024)
Koen P van Rhee, Catherijne A J Knibbe, P D van der Linden, Roger J M Brüggemann
Patients with Obesity Should be Recognised as a Special Patient Population During Drug Development of Antibacterial and Antifungal Agents; A Call to Action. Clinical pharmacokinetics 63 (1) (2024)
Xin Meng Mekking, Kirsten Velthoven-Graafland, Marga J A Teulen, Roger J M Brüggemann, Lindsey H M Te Brake, Nynke G L Jager
Development and validation of an UPLC-MS/MS assay for the simultaneous quantification of seven commonly used antibiotics in human plasma and its application in therapeutic drug monitoring. The Journal of antimicrobial chemotherapy 79 (4) (2024)
Omar Elkayal, Beatrijs Mertens, Joost Wauters, Yves Debaveye, Bart J A Rijnders, Paul E Verweij, Roger J M Brüggemann, Isabel Spriet, Erwin Dreesen
Dosing of IV posaconazole to treat critically ill patients with invasive pulmonary aspergillosis: a population pharmacokinetics modelling and simulation study. The Journal of antimicrobial chemotherapy (2024)
Xin Meng Mekking, Kirsten Velthoven-Graafland, Marga J A Teulen, Roger J M Brüggemann, Lindsey H M Te Brake, Nynke G L Jager
Development and validation of an UPLC-MS/MS assay for the simultaneous quantification of seven commonly used antibiotics in human plasma and its application in therapeutic drug monitoring. The Journal of antimicrobial chemotherapy 79 (4) (2024)
Mehmet Ergün, Anouk M E Jansen, Luuk B Hilbrands, Elizabeth A de Kort, Henricus Kunst, Monique H E Reijers, Jeroen A Schouten, Paul E Verweij, Roger J M Brüggemann
Isavuconazole as prophylaxis and therapy for invasive fungal diseases: a real-life observational study. The Journal of antimicrobial chemotherapy 79 (8) (2024)
Mehmet Ergün, Anouk M E Jansen, Luuk B Hilbrands, Elizabeth A de Kort, Henricus Kunst, Monique H E Reijers, Jeroen A Schouten, Paul E Verweij, Roger J M Brüggemann
Isavuconazole as prophylaxis and therapy for invasive fungal diseases: a real-life observational study. The Journal of antimicrobial chemotherapy (2024)
Martin Hoenigl, Amir Arastehfar, Maiken Cavling Arendrup, Roger J M Brüggemann, Agostinho Carvalho, Tom Chiller, Sharon Chen, Matthias Egger, Simon Feys, Jean-Pierre Gangneux, Jeremy A W Gold, Andreas H Groll, Jannes Heylen, Jeffrey D Jenks, Robert Krause, Katrien Lagrou, Frederic Lamoth, Juergen Prattes, Sarah Sedik, Joost Wauters, Nathan P Wiederhold, George R Thompson Iii
Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease. Clinical microbiology reviews 37 (2) (2024)
Martin Hoenigl, Amir Arastehfar, Maiken Cavling Arendrup, Roger J M Brüggemann, Agostinho Carvalho, Tom Chiller, Sharon Chen, Matthias Egger, Simon Feys, Jean-Pierre Gangneux, Jeremy A W Gold, Andreas H Groll, Jannes Heylen, Jeffrey D Jenks, Robert Krause, Katrien Lagrou, Frederic Lamoth, Juergen Prattes, Sarah Sedik, Joost Wauters, Nathan P Wiederhold, George R Thompson Iii
Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease. Clinical microbiology reviews 37 (2) (2024)
Omar Elkayal, Beatrijs Mertens, Joost Wauters, Yves Debaveye, Bart J A Rijnders, Paul E Verweij, Roger J M Brüggemann, Isabel Spriet, Erwin Dreesen
Dosing of IV posaconazole to treat critically ill patients with invasive pulmonary aspergillosis: a population pharmacokinetics modelling and simulation study. The Journal of antimicrobial chemotherapy 79 (7) (2024)
Martin Hoenigl, Amir Arastehfar, Maiken Cavling Arendrup, Roger J M Brüggemann, Agostinho Carvalho, Tom Chiller, Sharon Chen, Matthias Egger, Simon Feys, Jean-Pierre Gangneux, Jeremy A W Gold, Andreas H Groll, Jannes Heylen, Jeffrey D Jenks, Robert Krause, Katrien Lagrou, Frederic Lamoth, Juergen Prattes, Sarah Sedik, Joost Wauters, Nathan P Wiederhold, George R Thompson Iii
Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease. Clinical microbiology reviews 37 (2) (2024)
Xin Meng Mekking, Kirsten Velthoven-Graafland, Marga J A Teulen, Roger J M Brüggemann, Lindsey H M Te Brake, Nynke G L Jager
Development and validation of an UPLC-MS/MS assay for the simultaneous quantification of seven commonly used antibiotics in human plasma and its application in therapeutic drug monitoring. The Journal of antimicrobial chemotherapy 79 (4) (2024)
Koen P van Rhee, Catherijne A J Knibbe, P D van der Linden, Roger J M Brüggemann
Patients with Obesity Should be Recognised as a Special Patient Population During Drug Development of Antibacterial and Antifungal Agents; A Call to Action. Clinical pharmacokinetics 63 (1) (2024)
Martin Hoenigl, Amir Arastehfar, Maiken Cavling Arendrup, Roger J M Brüggemann, Agostinho Carvalho, Tom Chiller, Sharon Chen, Matthias Egger, Simon Feys, Jean-Pierre Gangneux, Jeremy A W Gold, Andreas H Groll, Jannes Heylen, Jeffrey D Jenks, Robert Krause, Katrien Lagrou, Frederic Lamoth, Juergen Prattes, Sarah Sedik, Joost Wauters, Nathan P Wiederhold, George R Thompson Iii
Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease. Clinical microbiology reviews 37 (2) (2024)
Martin Hoenigl, Amir Arastehfar, Maiken Cavling Arendrup, Roger J M Brüggemann, Agostinho Carvalho, Tom Chiller, Sharon Chen, Matthias Egger, Simon Feys, Jean-Pierre Gangneux, Jeremy A W Gold, Andreas H Groll, Jannes Heylen, Jeffrey D Jenks, Robert Krause, Katrien Lagrou, Frederic Lamoth, Juergen Prattes, Sarah Sedik, Joost Wauters, Nathan P Wiederhold, George R Thompson Iii
Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease. Clinical microbiology reviews (2024)
Omar Elkayal, Beatrijs Mertens, Joost Wauters, Yves Debaveye, Bart J A Rijnders, Paul E Verweij, Roger J M Brüggemann, Isabel Spriet, Erwin Dreesen
Dosing of IV posaconazole to treat critically ill patients with invasive pulmonary aspergillosis: a population pharmacokinetics modelling and simulation study. The Journal of antimicrobial chemotherapy 79 (7) (2024)
Koen P van Rhee, Catherijne A J Knibbe, P D van der Linden, Roger J M Brüggemann
Patients with Obesity Should be Recognised as a Special Patient Population During Drug Development of Antibacterial and Antifungal Agents; A Call to Action. Clinical pharmacokinetics 63 (1) (2024)
Xin Meng Mekking, Kirsten Velthoven-Graafland, Marga J A Teulen, Roger J M Brüggemann, Lindsey H M Te Brake, Nynke G L Jager
Development and validation of an UPLC-MS/MS assay for the simultaneous quantification of seven commonly used antibiotics in human plasma and its application in therapeutic drug monitoring. The Journal of antimicrobial chemotherapy (2024)
Koen P van Rhee, Catherijne A J Knibbe, P D van der Linden, Roger J M Brüggemann
Patients with Obesity Should be Recognised as a Special Patient Population During Drug Development of Antibacterial and Antifungal Agents; A Call to Action. Clinical pharmacokinetics (2024)
Mehmet Ergün, Anouk M E Jansen, Luuk B Hilbrands, Elizabeth A de Kort, Henricus Kunst, Monique H E Reijers, Jeroen A Schouten, Paul E Verweij, Roger J M Brüggemann
Isavuconazole as prophylaxis and therapy for invasive fungal diseases: a real-life observational study. The Journal of antimicrobial chemotherapy 79 (8) (2024)
Tan Zhang, Elke H J Krekels, Cornelis Smit, Eric P A van Dongen, Roger J M Brüggemann, Catherijne A J Knibbe
How to Dose Vancomycin in Overweight and Obese Patients with Varying Renal (Dys)function in the Novel Era of AUC 400-600 mg·h/L-Targeted Dosing. Clinical pharmacokinetics (2023)
Anouk M E Jansen, Beatrijs Mertens, Isabel Spriet, Paul E Verweij, Jeroen A Schouten, Joost Wauters, Yves Debaveye, Rob Ter Heine, Roger J M Brüggemann
Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies. Clinical pharmacokinetics (2023)
Julia Wilhelmina Korzilius, Michelle Gompelman, Guus T J Wezendonk, Nynke G L Jager, Chantal P Rovers, Roger J M Brüggemann, Geert J A Wanten
Oral antimicrobial agents in patients with short bowel syndrome: worth a try! The Journal of antimicrobial chemotherapy (2023)
Lu Chen, Elke H J Krekels, Anne R Heijnen, Catherijne A J Knibbe, Roger J M Brüggemann
An Integrated Population Pharmacokinetic Analysis for Posaconazole Oral Suspension, Delayed-Release Tablet, and Intravenous Infusion in Healthy Volunteers. Drugs 83 (1) (2023)
Lu Chen, Elke H J Krekels, Anne R Heijnen, Catherijne A J Knibbe, Roger J M Brüggemann
An Integrated Population Pharmacokinetic Analysis for Posaconazole Oral Suspension, Delayed-Release Tablet, and Intravenous Infusion in Healthy Volunteers. Drugs 83 (1) (2023)
Didi Bury, Tom F W Wolfs, Rob Ter Heine, Eline W Muilwijk, Kim C M van der Elst, Wim J E Tissing, Roger J M Brüggemann
Pharmacokinetic investigations of isavuconazole in paediatric cancer patients show reduced exposure of isavuconazole after opening capsules for administration via a nasogastric tube. The Journal of antimicrobial chemotherapy (2023)
Lu Chen, Elke H J Krekels, Anne R Heijnen, Catherijne A J Knibbe, Roger J M Brüggemann
An Integrated Population Pharmacokinetic Analysis for Posaconazole Oral Suspension, Delayed-Release Tablet, and Intravenous Infusion in Healthy Volunteers. Drugs (2023)
Anouk M E Jansen, Rob Ter Heine, J Peter Donnelly, Nicole Blijlevens, Roger J M Brüggemann
Repurposing antifungals: population pharmacokinetics of itraconazole and hydroxy-itraconazole following administration of a nanocrystal formulation. The Journal of antimicrobial chemotherapy (2023)
J W A Mouton, Jelmer Raaijmakers, M Botterblom, M Toonen, R Ter Heine, R L Smeets, Roger J M Brüggemann, L Te Brake, Nynke G L Jager
Development and validation of a bioanalytical assay for the measurement of total and unbound teicoplanin in human serum. The Journal of antimicrobial chemotherapy (2023)
Lu Chen, Elke H J Krekels, Anne R Heijnen, Catherijne A J Knibbe, Roger J M Brüggemann
An Integrated Population Pharmacokinetic Analysis for Posaconazole Oral Suspension, Delayed-Release Tablet, and Intravenous Infusion in Healthy Volunteers. Drugs 83 (1) (2023)
Charlotte D C C van der Heijden, Rob Ter Heine, Emma J Kooistra, Roger J M Brüggemann, Jesper W J Walburgh Schmidt, Elke P L M de Grouw, Tim Frenzel, Peter Pickkers, Jenneke Leentjens
Effects of dalteparin on anti-Xa activities cannot be predicted in critically ill COVID-19 patients. British journal of clinical pharmacology 88 (6) (2022)
Koen P van Rhee, Cornelis Smit, Roeland E Wasmann, Paul D van der Linden, Marinus J Wiezer, Eric P A Van Dongen, Elke H J Krekels, Roger J M Brüggemann, Catherijne A J Knibbe
Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals: A Prospective Clinical Study. Clinical pharmacokinetics 61 (8) (2022)
K P van Rhee, S L de Vroom, R M van Hest, P D van der Linden, S H Tonino, E Molendijk, R A A Mathôt, N M A Blijlevens, Catherijne A J Knibbe, Roger J M Brüggemann, S E Geerlings
Impact of mucositis on oral bioavailability and systemic exposure of ciprofloxacin Gram-negative infection prophylaxis in patients with haematological malignancies. The Journal of antimicrobial chemotherapy 77 (11) (2022)
Lu Chen, Koen P van Rhee, Roeland E Wasmann, Elke H J Krekels, Marinus J Wiezer, Eric P A van Dongen, Paul E Verweij, Paul D van der Linden, Roger J M Brüggemann, Catherijne A J Knibbe
Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults. The Journal of antimicrobial chemotherapy 77 (8) (2022)
Roger J M Brüggemann, G M Jensen, C Lass-Flörl
Liposomal amphotericin B-the past. The Journal of antimicrobial chemotherapy 77 (Suppl_2) (2022)
Didi Bury, Tom F W Wolfs, Rob Ter Heine, Eline W Muilwijk, Wim J E Tissing, Roger J M Brüggemann
Pharmacokinetic evaluation of twice-a-week micafungin for prophylaxis of invasive fungal disease in children with acute lymphoblastic leukaemia: a prospective observational cohort study. The Journal of antimicrobial chemotherapy 77 (3) (2022)
Ruth Van Daele, Joost Wauters, Erwin Dreesen, Jerina Boelens, Eric Nulens, Piet Lormans, Lore Vanderbeke, Cato Jacobs, Bart J A Rijnders, Paul E Verweij, Roger J M Brüggemann, Isabel Spriet
Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSA-FLU study. Mycoses 65 (6) (2022)
Beatrijs Mertens, Ruth Van Daele, Yves Debaveye, Joost Wauters, Christophe Vandenbriele, Roger J M Brüggemann, Matthias Gijsen, Isabel Spriet
Comment on: Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation. The Journal of antimicrobial chemotherapy 77 (12) (2022)
Stan J F Hartman, Parth J Upadhyay, Ron A A Mathôt, Michiel van der Flier, Michiel F Schreuder, Roger J M Brüggemann, Catherijne A J Knibbe, Saskia N de Wildt
Population pharmacokinetics of intravenous cefotaxime indicates that higher doses are required for critically ill children. The Journal of antimicrobial chemotherapy 77 (6) (2022)
Ruth Van Daele, Yves Debaveye, Robin Vos, Pascal Van Bleyenbergh, Roger J M Brüggemann, Erwin Dreesen, Omar Elkayal, Henk-Jan Guchelaar, Pieter Vermeersch, Katrien Lagrou, Isabel Spriet
Concomitant use of isavuconazole and CYP3A4/5 inducers: Where pharmacogenetics meets pharmacokinetics. Mycoses 64 (9) (2021)
Anouk van der Veen, Annemie Somers, Sophie Vanhaesebrouck, Rob Ter Heine, Roger J M Brüggemann, Karel Allegaert, Pieter A J G de Cock
Variation in vancomycin dosing and therapeutic drug monitoring practices in neonatal intensive care units. International journal of clinical pharmacy (2021)
Mehmet Ergün, Roger J M Brüggemann, Alexandra Serris, Sarah Dellière, Andreas van Arkel, Robbert G Bentvelsen, Tom Rijpstra, Simone van der Sar-van der Brugge, Katrien Lagrou, Nico A F Janssen, Jochem B Buil, Karin van Dijk, Willem J G Melchers, Monique H E Reijers, Jeroen A Schouten, Joost Wauters, Alan Cordey, Shuchita Soni, Philip Lewis White, Frank L van de Veerdonk, Paul E Verweij
Aspergillus Test Profiles and Mortality in Critically Ill COVID-19 Patients. Journal of clinical microbiology 59 (12) (2021)
Paul E Verweij, Roger J M Brüggemann, Elie Azoulay, Matteo Bassetti, Stijn I Blot, Jochem B Buil, Charlotte Théroude, Tom M Chiller, Cornelius J Clancy, Oliver Andreas Cornely, Pieter Depuydt, Philipp Köhler, Katrien Lagrou, Dylan W de Lange, Cornelia Lass-Flörl, Russell E Lewis, Olivier Lortholary, Peter Wei-Lun Liu, Johan A Maertens, M Hong Nguyen, Thomas F Patterson, Bart J A Rijnders, Alejandro Rodríguez, Thomas R Rogers, Jeroen A Schouten, Joost Wauters, Frank L van de Veerdonk, Ignacio Martín-Loeches
Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. Intensive care medicine 47 (8) (2021)
E W Muilwijk, Roger J M Brüggemann
Reply to Kara et al., "Might Confounding Factors Have an Effect on Suboptimal Dosing of Fluconazole in Critically Ill Patients?" Antimicrobial agents and chemotherapy 65 (2) (2021)
Fatima Zohra Delma, Abdullah M S Al-Hatmi, Roger J M Brüggemann, Willem J G Melchers, Gerrit Sybren de Hoog, Paul E Verweij, Jochem B Buil
Molecular Mechanisms of 5-Fluorocytosine Resistance in Yeasts and Filamentous Fungi. Journal of fungi (Basel, Switzerland) 7 (11) (2021)
Lore Vanderbeke, Nico A F Janssen, Dennis C J J Bergmans, Marc Bourgeois, Jochem B Buil, Yves Debaveye, Pieter Depuydt, Simon Feys, Greet Hermans, Oscar Hoiting, Ben van der Hoven, Cato Jacobs, Katrien Lagrou, Virginie Lemiale, Piet Lormans, Johan A Maertens, Philippe Meersseman, Bruno Mégarbane, Saad Nseir, Jos A H van Oers, Marijke Reynders, Bart J A Rijnders, Jeroen A Schouten, Isabel Spriet, Karin Thevissen, Arnaud W Thille, Ruth Van Daele, Frank L van de Veerdonk, Paul E Verweij, Alexander Wilmer, Roger J M Brüggemann, Joost Wauters, null null
Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial. Intensive care medicine 47 (6) (2021)
Didi Bury, Wim J E Tissing, Eline W Muilwijk, Tom F W Wolfs, Roger J M Brüggemann
Clinical Pharmacokinetics of Triazoles in Pediatric Patients. Clinical pharmacokinetics 60 (9) (2021)
Roger J M Brüggemann, Frank L van de Veerdonk, Paul E Verweij
The Challenge of Managing COVID-19 Associated Pulmonary Aspergillosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 73 (11) (2021)
Cornelis Smit, Sebastiaan Camiel Goulooze, Roger J M Brüggemann, Catherine M T Sherwin, Catherijne A J Knibbe
Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1-18 Years. The AAPS journal 23 (3) (2021)
Eline W Muilwijk, Dylan W de Lange, Jeroen A Schouten, Roeland E Wasmann, Rob Ter Heine, David M Burger, Angela Colbers, Pieter J Haas, Paul E Verweij, Peter Pickkers, Roger J M Brüggemann
Suboptimal Dosing of Fluconazole in Critically Ill Patients: Time To Rethink Dosing. Antimicrobial agents and chemotherapy 64 (10) (2020)
Rob Ter Heine, Ron J Keizer, Krista van Steeg, Elise J Smolders, Matthijs van Luin, Hieronymus J Derijks, Cornelis P C de Jager, Tim Frenzel, Roger J M Brüggemann
Prospective validation of a model-informed precision dosing tool for vancomycin in intensive care patients. British journal of clinical pharmacology 86 (12) (2020)
Lu Chen, Elke H J Krekels, Paul E Verweij, Jochem B Buil, Catherijne A J Knibbe, Roger J M Brüggemann
Pharmacokinetics and Pharmacodynamics of Posaconazole. Drugs 80 (7) (2020)
Paul E Verweij, Bart J A Rijnders, Roger J M Brüggemann, Elie Azoulay, Matteo Bassetti, Stijn I Blot, Charlotte Théroude, Cornelius J Clancy, Oliver Andreas Cornely, Tom M Chiller, Pieter Depuydt, Daniele Roberto Giacobbe, Nico A F Janssen, Bart Jan Kullberg, Katrien Lagrou, Cornelia Lass-Flörl, Russell E Lewis, Peter Wei-Lun Liu, Olivier Lortholary, Johan A Maertens, Ignacio Martín-Loeches, M Hong Nguyen, Thomas F Patterson, Thomas R Rogers, Jeroen A Schouten, Isabel Spriet, Lore Vanderbeke, Joost Wauters, Frank L van de Veerdonk
Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive care medicine 46 (8) (2020)
Cornelis Smit, Roeland E Wasmann, Sebastiaan Camiel Goulooze, Marinus J Wiezer, Eric P A van Dongen, Johan W Mouton, Roger J M Brüggemann, Catherijne A J Knibbe
Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals. British journal of clinical pharmacology 86 (2) (2020)
Elizabeth A de Kort, Heleen S de Lil, Manita E J Bremmers, Lenneke F J van Groningen, Nicole M A Blijlevens, Gerwin Huls, Roger J M Brüggemann, Suzanne van Dorp, Walter J F M van der Velden
Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation. PloS one 14 (3) (2019)
Roeland E Wasmann, Rob Ter Heine, Eric P van Dongen, David M Burger, Vincent J Lempers, Catherijne A Knibbe, Roger J M Brüggemann
Pharmacokinetics of Anidulafungin in Obese and Normal-Weight Adults. Antimicrobial agents and chemotherapy 62 (7) (2018)
Bas Vreugdenhil, Walter J F M van der Velden, Ton Feuth, Matthijs Kox, Peter Pickkers, Frank L van de Veerdonk, Nicole M A Blijlevens, Roger J M Brüggemann
Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole. British journal of clinical pharmacology 84 (9) (2018)
J M Boonstra, K C van der Elst, A Veringa, E M Jongedijk, Roger J M Brüggemann, R A Koster, G A Kampinga, J G Kosterink, T S van der Werf, J G Zijlstra, D J Touw, J W C Alffenaar
Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis. Antimicrobial agents and chemotherapy 61 (12) (2017)